Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Faster, Cleaner, Better.

Progenics Pharmaceuticals (PGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

Cash Flow for [[ item.sessionDateDisplayLong ]]

Fiscal Year End Date: 12/31

(Values in U.S. thousands)

	12-2014	12-2013	12-2012	12-2011	12-2010
Cash Flows From Operating Activities
Net Income	4,410	-42,572	-35,431	10,381	-69,725
Depreciation Amortization	3,221	1,858	1,324	2,066	2,853
Income taxes - deferred	-989	-362	0	0	N/A
Accounts receivable	2,770	4,114	-5,421	767	5,239
Other Working Capital	2,253	1,419	-6,746	-422	10,947
Other Operating Activity	2,061	-564	11,630	5,595	4,276
Operating Cash Flow	$13,726	$-36,107	$-34,644	$18,387	$-46,410

Cash Flows From Investing Activities
PPE Investments	-571	37	-377	-226	-2,171
Net Acquisitions	N/A	1,888	N/A	N/A	N/A
Sale Of Investment	2,400	1,100	100	300	1,700
Investing Cash Flow	$1,829	$3,025	$-277	$74	$-471

Cash Flows From Financing Activities
Common Stock Issued	37,887	40,149	23,654	3,726	3,896
Other Financing Activity	0	-45	0	0	0
Financing Cash Flow	$37,887	$40,104	$23,654	$3,726	$3,896

Beginning Cash Position	65,860	58,838	70,105	47,918	90,903
End Cash Position	119,302	65,860	58,838	70,105	47,918
Net Cash Flow	$53,442	$7,022	$-11,267	$22,187	$-42,985

Free Cash Flow
Operating Cash Flow	13,726	-36,107	-34,644	18,387	-46,410
Capital Expenditure	-714	-137	-767	-226	-2,171
Free Cash Flow	13,012	-36,244	-35,411	18,161	-48,581